Health products: AMMPS launches two digital platforms to report adverse effects

* The Moroccan Agency for Medicines and Health Products (AMMPS) launched two digital platforms on November 4th.
* The platforms are named VigiMobile and VigiUp.
* The objective is to collect reports of adverse events related to medicines, vaccines, and various health products to strengthen safety monitoring and detect risks earlier.
* VigiMobile is dedicated to reporting adverse events related to medicines and vaccines.
* VigiUp covers a wider range of products, including medical devices, laboratory reagents, personal hygiene/cosmetic products, and food supplements.
* The platforms are intended for citizens and healthcare professionals.
* A ceremony marked the launch, involving the Secretary General of the Ministry of Health and Social Protection and institutional representatives.
* The launch coincided with the "MedSafetyWeek 2026" awareness campaign (November 2nd to 8th).
* Officials called for developing health surveillance mechanisms and strengthening reporting culture among stakeholders.
* Professor Samir Ahid, Director General of AMMPS, highlighted the need to improve early risk detection capacity and participation in surveillance.

The deployment of VigiMobile and VigiUp reflects a systemic shift toward digitalized health governance, moving from traditional, reactive reporting to proactive, integrated surveillance. The dual focus—one for pharmaceuticals/vaccines (VigiMobile) and another for a wider spectrum of health products (VigiUp)—suggests an attempt at comprehensive risk management, acknowledging that adverse events are not confined to prescription drugs but span the entire ecosystem of health commodities. The emphasis placed on involving both citizens and healthcare professionals highlights a recognition that effective surveillance requires integrating frontline experience with official data streams.
The call for strengthening coordination across territorial networks points toward a structural challenge: the gap between centralized regulatory oversight (AMMPS) and decentralized implementation within local health systems. While the creation of digital tools addresses the information collection mechanism, the subsequent necessity for improved coordination suggests that the primary hurdle is not technological implementation but institutional and cultural alignment regarding data flow and accountability. The awareness campaign surrounding this launch attempts to bridge the gap between technical tools and the necessary cultural transformation required for effective reporting. A critical implication here is whether the focus on building new surveillance systems risks creating another layer of bureaucratic complexity if coordination between national bodies and local centers is not prioritized equally alongside the technological rollout.
What structures govern the flow of data from citizen reports through to risk mitigation? How does the reliance on public awareness campaigns (MedSafetyWeek) interact with the operational deployment of platforms, and do these efforts risk becoming separate initiatives rather than an integrated surveillance strategy? Does framing health reporting solely as a mechanism for risk detection inadvertently shift responsibility away from systemic failures within the supply chain or clinical practice itself?